Objective: To observe the effect of Guifu Dihuang pills combined tamsulosin hydrochloride sustained release capsules in treating benign prostatic hyperplasia (BPH) disease of kidney-yang deficiency syndrome. Method: One hundred and sixteen BPH patients were randomly divided into the control group (56 cases) and the observation group (60 cases) via a digital method. Patients in the control group received 0.2 mg tamsulosin hydrochloride sustained release capsules orally once every night. Based on the therapy of the control group

patients in the observation group added 6 g Guifu Dihuang pills orally twice daily. All patients in two groups received 12 weeks of treatment. International prostate symptom scores (I-PSS)

kidney-yang deficiency syndrome scores

and quality of life (QOL) scores caused by urination symptom were assessed. Moreover

post-void residual urine volumes (PVR)

the maximal urinary flow rates(Qmax) and average urinary flow rates (Qave) were measured. Prostate size and quality were tested through type-B ultrasonic. Enuresis nocturia frequencies were recorded. Result: The total curative effect in the observation group was 91.66%

which was superior to 76.78% in the control group (P <0.05). Scores of I-PSS

kidney-YANG deficiency syndrome

QOL in the observation group were less than those in the control group (P <0.01). The PVR in the observation group was lower (P <0.01)

the Qmax and Qave were higher than those in the control group (P <0.01). After therapy

prostate size and quality decreased as compared with the control group (P <0.01). Frequencies of enuresis nocturia were less than those in the control group (P <0.01). Conclusion: Guifu Dihuang pills combined tamsulosin could ameliorate lower urinery-tract syndrom

improve patients' QOL and ameliorate risk factors of clinical progression in treating BPH patients with kidney-yang syndrome

and it is worthy of further study.